Third Rock Ventures and Parse Biosciences announced a strategic collaboration to create an unprecedented atlas of 5 million T cell receptors (TCRs)...
Each shareholder is estimated to receive US$1.82 per share plus one CVR per common share - - Transaction expected to close in the first quarter of 20...
Net sales increase organically by +5.2% to € 5.3 billion; foreign exchange effects of –4.9%, portfolio effects of +0.7% EBI...
Collaboration will investigate how continuous flow cellular engineering and donor-to-dose manufacturing expertise may advance scalable, non-viral process...
Carolina Molecular Inc., a leading molecular testing services laboratory, and Pixelgen Technologies AB announced a partnership to expand access to ...
Nurami Medical, a company developing next-generation regenerative solutions for soft tissue repair, has announced successful completion of Phase 1 of...
Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet fut...
Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety pr...
Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recu...
Fibro dT platform offers a high-capacity solution for mRNA purification with chromatography cycle times under 15 minutes. Sustainable pe...
Facet Life Sciences, a leader in regulatory strategy and drug development services, announced a strategic partnership with XCancer®, a global leader ...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Adva...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on the discovery and d...
Bristol Myers Squibb to provide idecabtagene vicleucel (ide-cel) for Dispatch’s planned U.S. Phase 1 study, expected to initiate in 2026 Collabo...
© 2026 Biopharma Boardroom. All Rights Reserved.
